Mylan scores multiple sclerosis patent win over Biogen

Mylan has succeeded in having a key Biogen patent covering multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) invalidated by a US federal court.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.

Big Pharma

Supreme Court denies MS treatment patent petition

25 March 2021 The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.

Biotechnology

Biogen loses another battle over MS drug patent

21 September 2020 In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.

More on this story

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.

Big Pharma

Supreme Court denies MS treatment patent petition

25 March 2021 The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.

Biotechnology

Biogen loses another battle over MS drug patent

More on this story

Americas

Mylan’s NHK-Fintiv challenge denied by SCOTUS

20 January 2022 The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.

Big Pharma

Supreme Court denies MS treatment patent petition

25 March 2021 The US Supreme Court has denied a petition from Argentum Pharmaceuticals to review a Federal Circuit ruling covering a multiple sclerosis treatment patent.

Biotechnology

Biogen loses another battle over MS drug patent